TNF and focal segmental glomerulosclerosis: Furthermore, suggestions of tumor necrosis factor α (TNFα) being involved in the pathogenesis of FSGS and its recurrence, raised interest in anti-TNFα antibodies (Infliximab, Adalimumab) as a therapeutic option (Trachtman et al. 2015; Otalora et al. 2019).